United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
293.24
-4.44 (-1.49%)
At close: Jul 15, 2025, 4:00 PM
293.00
-0.24 (-0.08%)
After-hours: Jul 15, 2025, 5:21 PM EDT
United Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover United Therapeutics stock have a consensus rating of "Buy" and an average price target of $383.08, which forecasts a 30.64% increase in the stock price over the next year. The lowest target is $302 and the highest is $600.
Price Target: $383.08 (+30.64%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 2 | 2 | 4 | 4 | 4 | 4 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $348 → $328 | Hold | Maintains | $348 → $328 | +11.85% | Jul 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $350 → $330 | Buy | Maintains | $350 → $330 | +12.54% | Jul 8, 2025 |
| UBS | UBS | Strong Buy Maintains $410 → $385 | Strong Buy | Maintains | $410 → $385 | +31.29% | Jun 30, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $321 → $315 | Hold | Maintains | $321 → $315 | +7.42% | Jun 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $405 | Buy | Initiates | $405 | +38.11% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
3.30B
from 2.88B
Increased by 14.58%
Revenue Next Year
3.51B
from 3.30B
Increased by 6.34%
EPS This Year
28.58
from 24.64
Increased by 15.98%
EPS Next Year
29.10
from 28.58
Increased by 1.82%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.5B | 3.8B | 4.6B | ||
| Avg | 3.3B | 3.5B | 3.6B | ||
| Low | 3.0B | 3.0B | 2.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 14.8% | 31.8% | ||
| Avg | 14.6% | 6.3% | 3.5% | ||
| Low | 4.5% | -9.0% | -16.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.46 | 32.97 | 41.06 | ||
| Avg | 28.58 | 29.10 | 29.43 | ||
| Low | 24.69 | 22.30 | 18.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.7% | 15.4% | 41.1% | ||
| Avg | 16.0% | 1.8% | 1.1% | ||
| Low | 0.2% | -22.0% | -37.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.